AbbVie

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final European Commission decision on this […]

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the foundation of the NHS.  As […]